7 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Selecta Biosciences, Inc. | 6 |
| Cartesian Therapeutics, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18933195 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | Cartesian Therapeutics, Inc. | GREENE, IVAN A | 1619 | Final Rejection | Oct 31, 2024 |
| 18343340 | VIRAL VECTOR DOSING PROTOCOLS | Selecta Biosciences, Inc. | MOORE, JOHN DAVID | 1638 | Non-Final OA | Jun 28, 2023 |
| 18119006 | IMMUNOSUPPRESSANTS IN COMBINATION WITH ANTI-IGM AGENTS AND RELATED DOSING | Selecta Biosciences, Inc. | POPA, ILEANA | 1633 | Non-Final OA | Mar 08, 2023 |
| 18094707 | HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND SYNTHETIC NANOCARRIER DOSE SPARING | Selecta Biosciences, Inc. | JUEDES, AMY E | 1644 | Non-Final OA | Jan 09, 2023 |
| 18063610 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES | Selecta Biosciences, Inc. | DIBRINO, MARIANNE | 1641 | Non-Final OA | Dec 08, 2022 |
| 17092148 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | Selecta Biosciences, Inc. | CURRENS, GRANT CARSON | 1651 | Final Rejection | Nov 06, 2020 |
| 14296204 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS | Selecta Biosciences, Inc. | HALVORSON, MARK | 1646 | Non-Final OA | Jun 04, 2014 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial